PATH | VRL
Menu

Efficacy of a Novel, Protein-Based Pneumococcal Vaccine Against Nasopharyngeal Carriage of Streptococcus pneumoniae in Infants: A Phase 2, Randomized, Controlled, Observer-Blind Study

This article, published in Vaccine, assessed the efficacy of two formulations of a pneumococcal vaccine candidate against nasopharyngeal carriage (NPC) prevalence in infants in The Gambia. It examined the impact of the two vaccine formulations on NPC in healthy infants as well as their reactogenicity, safety, and immunogenicity when given in a three-dose schedule together with routine Expanded Programme on Immunization vaccines. The authors found that inclusion of pneumococcal proteins in the investigational vaccine had no impact on pneumococcal NPC in infants, regardless of protein dose or schedule. However, these findings do not preclude protection against disease, and future evaluations will assess the impact of such vaccine formulations against pneumococcal disease endpoints.

Author: Odutola A, Ota MOC, Antonio M, et al.

Published: 2017

» Visit web page (English)

(Located at www.sciencedirect.com)

Citation: Odutola A, Ota MOC, Antonio M, et al. Efficacy of a Novel, Protein-Based Pneumococcal Vaccine Against Nasopharyngeal Carriage of Streptococcus pneumoniae in Infants: A Phase 2, Randomized, Controlled, Observer-Blind Study. Vaccine. 2017;35(19):2531–2542.

Resource types: Peer-reviewed journal

Diseases/vaccines: Pneumococcus

Topics: Vaccine safety and performance, Disease/vaccine specific information, Vaccine stabilization and formulation

Regions: Africa